

TRIPOD Checklist: Prediction Model Development and Validation

Section	Item		Checklist description	Reported on Page Number/Line Number	Reported on Section/Paragraph
Title and abstract					
Title	1	D;V	Identify the study as developing and/or validating a multivariable prediction model, the target population, and the outcome to be predicted.	PAGE 1, LINE 2	title
Abstract	2	D;V	Provide a summary of objectives, study design, setting, participants, sample size, predictors, outcome, statistical analysis, results, and conclusions.	PAGE 2, LINE 25-46	abstract
Introduction					
Background and objectives	3a	D;V	Explain the medical context (including whether diagnostic or prognostic) and rationale for developing or validating the multivariable prediction model, including references to existing models.	PAGE 3-4, LINE 48-96	introduction, para 1-3
	3b	D;V	Specify the objectives, including whether the study describes the development or validation of the model or both.	PAGE 4, LINE 97-108	introduction, para 4
Methods					
Source of data	4a	D;V	Describe the study design or source of data (e.g., randomized trial, cohort, or registry data), separately for the development and validation data sets, if applicable.	PAGE 5, LINE 110-117	method para 1
	4b	D;V	Specify the key study dates, including start of accrual; end of accrual; and, if applicable, end of follow-up.	NA	NA
Participants	5a	D;V	Specify key elements of the study setting (e.g., primary care, secondary care, general population) including number and location of centres.	NA	NA
	5b	D;V	Describe eligibility criteria for participants.	PAGE 5, LINE 114-117	method para 1
	5c	D;V	Give details of treatments received, if relevant.	NA	NA
Outcome	6a	D;V	Clearly define the outcome that is predicted by the prediction model, including how and when assessed.	PAGE 7, LINE 151-159	method para 6
	6b	D;V	Report any actions to blind assessment of the outcome to be predicted.	NA	NA
Predictors	7a	D;V	Clearly define all predictors used in developing or validating the multivariable prediction model, including how and when they were measured.	NA	NA
	7b	D;V	Report any actions to blind assessment of predictors for the outcome and other predictors.	PAGE 7, LINE 118-150	method para 2-5
Sample size	8	D;V	Explain how the study size was arrived at.	PAGE 5, LINE 111-115	method para 1

Missing data	9	D;V	Describe how missing data were handled (e.g., complete-case analysis, single imputation, multiple imputation) with details of any imputation method.	PAGE 5, LI NE 115–117	meth od para 1
Statistical analysis methods	10a	D	Describe how predictors were handled in the analyses.	PAGE 7, LI NE 152–154	meth od para 6
	10b	D	Specify type of model, all model-building procedures (including any predictor selection), and method for internal validation.	PAGE 7, LI NE 152–158	meth od para 6
	10c	V	For validation, describe how the predictions were calculated.	PAGE 7, LI NE 154–158	meth od para 6
	10d	D;V	Specify all measures used to assess model performance and, if relevant, to compare multiple models.	PAGE 7, LI NE 156–158	meth od para 6
	10e	V	Describe any model updating (e.g., recalibration) arising from the validation, if done.	NA	NA
Risk groups	11	D;V	Provide details on how risk groups were created, if done.	PAGE 7, LI NE 155–156	meth od para 6
Development vs. validation	12	V	For validation, identify any differences from the development data in setting, eligibility criteria, outcome, and predictors.	PAGE 7, LI NE 152–159	meth od para 6
Results					
Participants	13a	D;V	Describe the flow of participants through the study, including the number of participants with and without the outcome and, if applicable, a summary of the follow-up time. A diagram may be helpful.	PAGE 7–8 LI NE 160–180	resul t para 1
	13b	D;V	Describe the characteristics of the participants (basic demographics, clinical features, available predictors), including the number of participants with missing data for predictors and outcome.	NA	NA
	13c	V	For validation, show a comparison with the development data of the distribution of important variables (demographics, predictors and outcome).	NA	NA
Model development	14a	D	Specify the number of participants and outcome events in each analysis.	NA	NA
	14b	D	If done, report the unadjusted association between each candidate predictor and outcome.	NA	NA
Model specification	15a	D	Present the full prediction model to allow predictions for individuals (i.e., all regression coefficients, and model intercept or baseline survival at a given time point).	PAGE 8 LI NE 180–193	resul t para 2
	15b	D	Explain how to use the prediction model.	NA	NA
Model performance	16	D;V	Report performance measures (with CIs) for the prediction model.	PAGE 7–8 LI NE 160–193	resul t para 1–2
Model-updating	17	V	If done, report the results from any model updating (i.e., model specification, model performance).	NA	NA
Discussion					
Limitations	18	D;V	Discuss any limitations of the study (such as nonrepresentative sample, few events per predictor, missing data).	PAGE 13 LI NE 318–322	di scssi on para 6

Interpretation	19a	V	For validation, discuss the results with reference to performance in the development data, and any other validation data.	NA	NA
	19b	D;V	Give an overall interpretation of the results, considering objectives, limitations, and results from similar studies, and other relevant evidence.	PAGE 13 LINE 310–316	discussi on para 6
Implications	20	D;V	Discuss the potential clinical use of the model and implications for future research.	PAGE 13 LINE 317–322	Concl usi on
Other information					
Supplementary information	21	D;V	Provide information about the availability of supplementary resources, such as study protocol, Web calculator, and data sets.	Suppl ement ary tabl e	Suppl ement ary tabl e
Funding	22	D;V	Give the source of funding and the role of the funders for the present study.	PAGE 13 LINE 325–327	Fundi ng

* Items relevant only to the development of a prediction model are denoted by D, items relating solely to a validation of a prediction model are denoted by V, and items relating to both are denoted D;V. We recommend using the TRIPOD Checklist in conjunction with the TRIPOD Explanation and Elaboration document.

Article Information: <https://dx.doi.org/10.21037/tau-23-649>

*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.